RankingsPricing
  1. JP-listed companies
  2. Carna Biosciences, Inc.
  3. Financials
  4. Total liabilities

Carna Biosciences, Inc.JP:4572

Market cap
¥7.7B
P/E ratio
-3.6x
SummaryFinancialsHistorySegmentsOwnershipWorkforce
Period EndTotal liabilities (Million JPY)YoY (%)
Dec 31, 2024297-37.17%
Dec 31, 2023472-24.38%
Dec 31, 2022625-44.08%
Dec 31, 20211,117+10.45%
Dec 31, 20201,011-33.60%
Dec 31, 20191,523+72.56%
Dec 31, 2018883+8.64%
Dec 31, 2017812-1.75%
Dec 31, 2016827+77.04%
Dec 31, 2015467+19.40%
Dec 31, 2014391

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)